[1]刘晓莲.重组人干扰素α-2b阴道泡腾片联合保妇康栓治疗宫颈癌前病变合并高危型HPV感染的疗效[J].医学信息,2024,37(06):143-146.[doi:10.3969/j.issn.1006-1959.2024.06.025]
　LIU Xiao-lian.Efficacy of Recombinant Human Interferon α-2b Vaginal Effervescent Capsule Combined with Baofukang Suppository in the Treatment of Cervical Precancerous Lesions with High-risk HPV Infection[J].Journal of Medical Information,2024,37(06):143-146.[doi:10.3969/j.issn.1006-1959.2024.06.025]
点击复制

重组人干扰素α-2b阴道泡腾片联合保妇康栓治疗宫颈癌前病变合并高危型HPV感染的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年06期
页码:
143-146
栏目:
论著
出版日期:
2024-03-15

文章信息/Info

Title:
Efficacy of Recombinant Human Interferon α-2b Vaginal Effervescent Capsule Combined with Baofukang Suppository in the Treatment of Cervical Precancerous Lesions with High-risk HPV Infection
文章编号:
1006-1959（2024）06-0143-04
作者:
刘晓莲
（泰和县妇幼保健计划生育服务中心妇女保健部，江西 泰和 343700）
Author(s):
LIU Xiao-lian
(Women ’s Health Department of Taihe County Maternal and Child Health Family Planning Service Center,Taihe 343700,Jiangxi,China)
关键词:
宫颈癌前病变; 高危型HPV感染; 重组人干扰素α-2b阴道泡腾片; 保妇康栓
Keywords:
Cervical precancerous lesions; High-risk HPV infection; Recombinant human interferon α- 2b vaginal effervescent capsule; Baofukang suppository
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2024.06.025
文献标志码:
A
摘要:
目的 探究重组人干扰素α-2b阴道泡腾片（RHIα2b-VEC）联合保妇康栓治疗宫颈癌前病变（CIN）合并高危型人乳头瘤病毒（HPV）感染的临床价值。方法 收集2020年7月-2023年1月泰和县妇幼保健计划生育服务中心收治的66例CIN合并高危型HPV感染者，经随机数字表法分为对照组（33例）与观察组（33例）。对照组行保妇康栓治疗，观察组在其基础上联合RHIα2b-VEC治疗，比较两组HPV清除疗效、综合疗效、血清炎症指标[白细胞介素-4（IL-4）、白细胞介素-12（IL-12）]、T淋巴细胞水平（CD8+、CD4+、CD4+/CD8+）、不良反应。结果 观察组HPV清除有效率为63.64%，高于对照组的39.39%（P＜0.05）；观察组综合治疗有效率为60.61%，高于对照组的33.33%（P＜0.05）；观察组治疗后IL-4、CD8+低于对照组，IL-12、CD4+、CD4+/CD8+水平高于对照组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 RHIα2b-VEC联合保妇康栓治疗CIN合并高危型HPV感染的疗效良好，可提高其HPV转阴效果，调节细胞因子，改善免疫功能，且不增加不良反应发生几率。
Abstract:
Objective To explore the clinical value of recombinant human interferon α-2b vaginal effervescent capsule (RHIα2b-VEC) combined with Baofukang suppository in the treatment of cervical precancerous lesions (CIN) complicated with high-risk human papillomavirus (HPV) infection.Methods A total of 66 patients with CIN complicated with high-risk HPV infection admitted to Taihe County Maternal and Child Health Family Planning Service Center from July 2020 to January 2023 were collected and divided into control group (33 patients) and observation group (33 patients) by random number table method. The control group was treated with Baofukang suppository, and the observation group was treated with RHIα2 b-VEC on the basis of the control group. The HPV clearance efficacy, comprehensive efficacy, serum inflammatory indexes [interleukin-4 (IL-4), interleukin-12 (IL-12)], T lymphocyte levels (CD8+, CD4+, CD4+/CD8+) and adverse reactions were compared between the two groups.Results The effective rate of HPV clearance in the observation group was 63.64%, which was higher than 39.39% in the control group (P<0.05). The effective rate of comprehensive treatment in the observation group was 60.61%, which was higher than 33.33% in the control group (P<0.05). After treatment, the levels of IL-4 and CD8+ in the observation group were lower than those in the control group, and the levels of IL-12, CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion RHIα2b-VEC combined with Baofukang suppository is effective in the treatment of CIN complicated with high-risk HPV infection, which can improve the negative conversion effect of HPV, regulate cytokines, improve immune function, and do not increase the incidence of adverse reactions.

参考文献/References:

[1]李二雷,刘冬梅,安国倩,等.抗HPV生物凝胶敷料辅助保妇康栓治疗HPV感染性宫颈炎的临床意义[J].现代生物医学进展,2022,22(23):4516-4520.[2]姜歆宇,岳亚琳.保妇康栓联合重组人干扰素α-2b对慢性宫颈炎合并HPV感染患者HPV转阴的影响[J].中国妇幼保健,2022,37(20):3753-3756.[3]支雄莉,赵娜,田霞,等.保妇康栓联合瑞贝生对宫颈高危型HPV感染患者细胞免疫功能的影响[J].河北医药,2022,44(15):2357-2360.[4]朱丽芳,徐燕.保妇康栓联合干扰素α-2b治疗慢性宫颈炎合并人乳头瘤病毒感染的疗效[J].海军医学杂志,2021,42(3):343-346.[5]吕小可,陈莉,代雪莹.阿奇霉素与保妇康栓联用对慢性宫颈炎伴HPV感染的结局影响[J].贵州医药,2021,45(9):1419-1420.[6]王亚男,胡萃,刘双.保妇康栓在慢性宫颈炎合并HPV持续感染治疗中的效果分析[J].检验医学与临床,2021,18(18):2688-2690.[7]麦燕,麦燕婷.重组人干扰素α-2b联合保妇康栓治疗慢性宫颈炎合并人乳头瘤病毒感染效果分析[J].山西医药杂志,2018,47(3):283-284.[8]何秋玲,刘冬艳.重组人干扰素α2b阴道泡腾片联合抗宫炎片治疗慢性宫颈炎合并人乳头瘤病毒感染的临床效果[J].广西医学,2021,43(10):1201-1204.[9]唐宇星,王敏,张诗敏,等.不同药物对高危型HPV持续感染及宫颈癌前病变合并高危型HPV感染的临床疗效对比研究[J].实用药物与临床,2022,25(5):385-391.[10]王运萍,徐佳,李砚,等.保妇康栓联合干扰素栓对高危型人乳头瘤病毒感染患者的效果及HPV-DNA、炎性因子、免疫功能的变化[J].贵州医药,2021,45(1):39-40.[11]王璐,黄晓桃,葛曼,等.重组人干扰素α-2b凝胶联合乳酸菌阴道胶囊对宫颈高危型HPV持续感染的治疗[J].中国微生态学杂志,2020,32(12):1449-1453.[12]李玉仙.重组人干扰素α-2b栓联合保妇康栓对慢性宫颈炎合并人乳头瘤病毒感染的疗效观察[J].中国药物与临床,2020,20(14):2385-2387.[13]苏小玉,蒙莉萍,邹聪聪,等.重组人干扰素凝胶联合保妇康栓治疗宫颈高危型HPV感染的临床观察[J].中国药房,2020,31(8):984-988.[14]武春梅,张爱英.保妇康栓联合重组人干扰素α-2b治疗慢性宫颈炎合并高危型HPV感染临床研究[J].湖北中医药大学学报,2019,21(6):69-71.[15]江海芳.重组人干扰素α-2b联合保妇康栓治疗慢性宫颈糜烂合并HPV感染的效果观察[J].中国临床新医学,2019,12(10):1124-1126.[16]韩亚琴,张玲玲,代庆林,等.重组人干扰素α-2b栓联合保妇康栓治疗慢性宫颈炎合并高危型HPV感染的临床研究[J].川北医学院学报,2019,34(3):422-424.[17]赵秀梅,金玲,常春玲,等.复方沙棘籽油栓联合重组人干扰素α2b栓治疗人乳头瘤病毒感染合并慢性宫颈炎的效果及对患者免疫功能和炎性因子水平的影响[J].中国医药,2019,14(11):1689-1693.[18]包存芳,陈冀莹,张惠玲,等.保妇康栓联合干扰素栓对宫颈HPV感染患者的效果及HPV DNA、炎性因子、免疫功能的变化[J].解放军预防医学杂志,2019,37(2):149-150.[19]贾利平,刘玉珠,周小飞,等.重组人干扰素α-2b联合保妇康栓对HPV感染患者的治疗效果[J].中华医院感染学杂志,2019,29(5):749-752.[20]蔡昱,翟建军,段仙芝.重组人白细胞介素2联合保妇康栓治疗HPV感染性宫颈炎的临床效果观察[J].广西医学,2018,40(22):2666-2667,2671.[21]姬静.保妇康栓联合冷冻治疗慢性宫颈炎伴HPV感染疗效及对HPV转阴率、血清炎症因子的影响[J].慢性病学杂志,2018,19(10):1366-1367,1370.[22]王转红,王峥,刘欢,等.康复新液联合保妇康栓治疗慢性宫颈炎伴HPV感染疗效观察[J].中医学报,2018,33(8):1576-1579.[23]冯小丽,刘继红,李聪.重组人干扰素α-2b与保妇康栓阴道放置对宫颈高危HPV感染患者的疗效及免疫功能的影响[J].河北医药,2018,40(7):1083-1085.[24]陈洁,范李鑫,曹春园.重组人干扰素α-2b阴道泡腾片治疗宫颈癌前病变合并高危型人乳头瘤病毒感染的效果分析[J].中国性科学,2021,30(6):98-101.[25]赵四平,张平,张蒙.重组人干扰素α-2b阴道泡腾片联合微波治疗慢性宫颈炎伴HPV感染的临床研究[J].四川生理科学杂志,2022,44(10):1777-1779.

相似文献/References:

[1]祝亚军.高危型HPV-DNA及TCT检测筛查宫颈癌及宫颈癌前病变的价值[J].医学信息,2019,32(22):157.[doi:10.3969/j.issn.1006-1959.2019.22.054]
　ZHU Ya-jun.The Value of Screening High-Risk HPV-DNA and TCT for Cervical Carcinoma and Cervical Precancerous Lesions[J].Journal of Medical Information,2019,32(06):157.[doi:10.3969/j.issn.1006-1959.2019.22.054]
[2]穆红茹.电子阴道镜下定位活检在宫颈病变诊断中的应用价值[J].医学信息,2022,35(01):178.[doi:10.3969/j.issn.1006-1959.2022.01.045]
　MU Hong-ru.Application Value of Localization Biopsy Under Electronic Colposcopy in Diagnosis of Cervical Lesions[J].Journal of Medical Information,2022,35(06):178.[doi:10.3969/j.issn.1006-1959.2022.01.045]
[3]见永康,吴泽俊,庄雅丽.宫颈癌筛查联合阴道镜活检防治宫颈癌前病变的价值研究[J].医学信息,2023,36(16):117.[doi:10.3969/j.issn.1006-1959.2023.16.022]
　JIAN Yong-kang,WU Ze-jun,ZHUANG Ya-li.Study on the Value of Cervical Cancer Screening Combined with Colposcopy Biopsy in the Prevention and Treatment of Cervical Precancerous Lesions[J].Journal of Medical Information,2023,36(06):117.[doi:10.3969/j.issn.1006-1959.2023.16.022]
[4]李 娟.阴道镜联合宫颈环形电切术治疗宫颈癌前病变的临床效果及对术后妊娠情况的影响[J].医学信息,2023,36(21):126.[doi:10.3969/j.issn.1006-1959.2023.21.029]
　LI Juan.Clinical Effect of Colposcopy Combined with Loop Electrosurgical Excision Procedure in the Treatment of Cervical Precancerous Lesions and its Effect on Postoperative Pregnancy[J].Journal of Medical Information,2023,36(06):126.[doi:10.3969/j.issn.1006-1959.2023.21.029]
[5]赖丽娟.宫颈环形电切术治疗宫颈癌前病变的效果[J].医学信息,2024,37(12):137.[doi:10.3969/j.issn.1006-1959.2024.12.031]
　LAI Li-juan.Effect of Loop Electrosurgical Excision Procedure in the Treatment of Precancerous Lesions of Uterine Cervix[J].Journal of Medical Information,2024,37(06):137.[doi:10.3969/j.issn.1006-1959.2024.12.031]
[6]聂俊玲,江小华,刘庆春,等.重组人干扰素α2a栓联合康妇凝胶治疗对高危型HPV感染患者免疫功能及转阴率的影响[J].医学信息,2024,37(21):70.[doi:10.3969/j.issn.1006-1959.2024.21.015]
　NIE Junling,JIANG Xiaohua,LIU Qingchun,et al.Effect of Recombinant Human Interferon α2a Suppository Combined with Kangfu Gel on Immune Function and Negative Conversion Rate in Patients with High-risk HPV Infection[J].Journal of Medical Information,2024,37(06):70.[doi:10.3969/j.issn.1006-1959.2024.21.015]
[7]彭雪琴.宫颈上皮内瘤变宫颈锥切术后复发的影响因素分析[J].医学信息,2025,38(05):136.[doi:10.3969/j.issn.1006-1959.2025.05.023]
　PENG Xueqin.Analysis of Influencing Factors of Recurrence After Cervical Conization of Cervical Intraepithelial Neoplasia[J].Journal of Medical Information,2025,38(06):136.[doi:10.3969/j.issn.1006-1959.2025.05.023]

更新日期/Last Update: 1900-01-01